• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Unique cytokine signature in the plasma of patients with fibromyalgia

Ecoclimber

Senior Member
Messages
1,011
J Immunol Res. 2014;2014:938576. doi: 10.1155/2014/938576. Epub 2014 Mar 11.
Unique cytokine signature in the plasma of patients with fibromyalgia.

Sturgill J1, McGee E2, Menzies V1.
Author information

  • 1School of Nursing, Virginia Commonwealth University, Richmond, VA 23298, USA ; Institute of Women's Health, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • 2Institute of Women's Health, Virginia Commonwealth University, Richmond, VA 23298, USA ; Department of Obstetrics, Gynecology and Reproductive Sciences, University of Vermont, Burlington, VT 05401, USA.
Abstract

Fibromyalgia (FMS) is a chronic pain syndrome with a complex but poorly understood pathogenesis affecting approximately 10 million adults in the United States. The lack of a clear etiology of FMS has limited the effective diagnosis and treatment of this debilitating condition.

The objective of this secondary data analysis was to examine plasma cytokine levels in women with FMS using the Bio-Plex Human Cytokine 17-plex Assay. Post hoc analysis of plasma cytokine levels was performed to evaluate patterns that were not specified a priori. Upon examination, patients with FMS exhibited a marked reduction in TH2 cytokines such as IL-4, IL-5, and IL-13.

The finding of this pattern of altered cytokine milieu not only supports the role of inflammation in FMS but also may lead to more definitive diagnostic tools for clinicians treating FMS. The TH2 suppression provides strong evidence of immune dysregulation in patients with FMS.